▶ Reels

“Emerging ‘Cicada’ COVID‑19 Variant BA.3.2 in the U.S.: What You Need to Know About Spread, Symptoms, and Risks”

 


🦠 What is the BA.3.2 (“Cicada”) COVID‑19 Variant?

The BA.3.2 variant — nicknamed “Cicada” — is a newly detected sub‑lineage of the SARS‑CoV‑2 virus (the virus that causes COVID‑19). It is part of the larger Omicron family of variants and has been classified by the World Health Organization (WHO) as a Variant Under Monitoring (VUM) due to its large number of genetic changes and immune escape potential.

Scientists first identified BA.3.2 in South Africa in November 2024. Since then, genomic surveillance has shown it spreading internationally, including in at least 25 U.S. states and over 20 other countries


🔬 Key Characteristics

Heavily Mutated Spike Protein:

  • BA.3.2 carries approximately 70–75 mutations, especially in the spike protein — the part of the virus targeted by vaccines and many antibody responses. 

  • These changes can give it immune escape characteristics, meaning it may partially evade immunity from past infection or vaccination. 

Detection Trends:

  • In the U.S., it has been found through wastewater surveillance and clinical samples, signaling broader—but still relatively low—circulation compared with dominant variants. 

  • As of the latest CDC data, BA.3.2 represents a small share of sequenced cases nationwide. 


🧪 How It’s Being Monitored

Public health agencies like the U.S. Centers for Disease Control and Prevention (CDC) use genomic sequencing and wastewater surveillance to track emerging variants. BA.3.2 was first identified in the U.S. via traveler monitoring and has been increasingly detected across different surveillance systems. 

Because of its mutation profile and potential for immune escape, scientists are watching its spread closely to understand whether it will grow in prevalence or remain a minor lineage. 


🤧 Symptoms Associated With BA.3.2

Reported symptoms for BA.3.2 generally resemble those seen with earlier Omicron‑related COVID‑19 variants and include: 

  • Cough

  • Fever or chills

  • Fatigue

  • Headache

  • Sore throat

  • Upper respiratory symptoms (sneezing, nasal congestion)

  • Body aches

  • Less commonly, loss of smell or taste

Like with other variants, some infections may be asymptomatic — especially in vaccinated individuals or those with recent COVID‑19 infection. 


🧑‍⚕️ Risk Factors & Who’s Most At Risk

People with weakened immune systems, older adults, and those with underlying health conditions remain at higher risk for severe illness from COVID‑19—including BA.3.2 or other variants. Vaccination and updated boosters continue to provide protection against serious outcomes, even if breakthrough infections occur. 

While BA.3.2 might partially evade immune defenses, current evidence suggests that vaccines still help reduce the risk of hospitalization and death. 


🛡️ What You Should Know

  • BA.3.2 is being tracked but is not currently causing a major surge in cases in the U.S. compared with other circulating variants. 

  • Vaccines and boosters remain key tools for reducing severe outcomes.

  • Healthcare experts recommend staying up to date on vaccinations and seeking testing if you develop symptoms. 


Related Blogs


Is it safe to take antibiotics frequently?

April 16, 2026

Antibiotics have revolutionized modern medicine, h...

READ MORE

Modern Healthcare Tips to Keep You Fit, Active, and Illness-Free

April 15, 2026

In today’s fast-paced lifestyle, staying healthy...

READ MORE

From Morning to Night: Smart Lifestyle Changes for Better Health & Disease Prevention

April 14, 2026

Living a healthy life doesn’t require extreme ch...

READ MORE

How to Reduce Snoring Fast: Lifestyle Changes That Make a Difference

April 13, 2026

Snoring isn’t just a nighttime annoyance—it ca...

READ MORE

Snoring vs Sleep Apnea: Key Differences & When to Seek Help

April 11, 2026

Snoring may seem harmless—even funny at times—...

READ MORE
About Health Expert

The Health Expert...


Follow Us


Copyright © The Health Expert. All rights reserved.